Tag: VEITHsymposium
Frank J Veith joins ViTAA Medical Solutions’ board of directors
ViTAA Medical Solutions has announced the appointment of Frank J Veith, professor of surgery at the Cleveland Clinic Lerner College of Medicine of Case...
LIMIT trial: Could metformin be first-ever medical treatment that is effective...
There is a global interest in assessing whether Metformin, which has a long track record of safety and efficacy, is relatively inexpensive and is...
Randomised trial set to elucidate value of image fusion technology for...
An ongoing UK National Institute for Health and Care Research (NIHR)-funded randomised controlled trial seeks to illuminate the value of an image fusion guidance...
Two-year SWING data “continue to show promise” for sirolimus DCB in...
Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been...
VentureMed to present new data on DCB treatment for PAD
VentureMed Group has announced new data presentations on the treatment of peripheral arterial disease (PAD) with drug-coated balloon (DCBs) in addition to 12-month AV...
VEITH 2021: Two-year follow-up data from EVAS2 IDE study delivered
The confirmatory EVAS2 clinical study to evaluate the safety and effectiveness of the Nellix endovascular aneurysm sealing system (EVAS; Endologix) for the treatment of...
Customising therapy in femoropopliteal revascularisation
Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based therapies have become a mainstay in femoropopliteal revascularisation and how interventionalists...
Be an early adopter of AI to harness its benefits
Artificial intelligence (AI) is already better than humans at reading specific radiographic findings. It will impact phycisians’ jobs, but because it can currently only...
PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in...
Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at...
Lutonix BTK IDE: First Level 1 evidence of positive safety and...
Patrick Geraghty (St Louis, USA) presented new datapoints from the six-month outcomes of the Lutonix BTK IDE trial at the 2018 VEITHsymposium (13–17 November,...
